Study of Nivolumab for Advanced Cancers in India

Sponsor
Bristol-Myers Squibb
Study ID
NCT03444766
Phase
PHASE4
Status
Completed

Conditions

  • Kidney Cancer
  • Kidney Neoplasms
  • Non-Small Cell Lung Cancer (NSCLC)
  • Non-Small-Cell Lung Carcinoma
  • Nonsmall Cell Lung Cancer
  • Renal Cancer
  • Renal Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    specified dose on specified days

Study Details

This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.

Key Dates

Start date
Mar 6, 2018
Status verified
Dec 2020
Primary completion
Jul 17, 2019
Completion
Jul 17, 2019

Study Design

Enrollment
100 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Monotherapy
    administering nivolumab only

Primary Outcome Measure

Number of Participants With Treatment-related Adverse Events [ Time Frame: 26 Weeks ]

Related Studies